Anatara Lifesciences Ltd (ASX: ANR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anatara Lifesciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.64 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
192.89 million
Earnings per share
-0.013
Dividend per share
N/A
Year To Date Return
104.55%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anatara Lifesciences Ltd (ASX: ANR)
Latest News
Share Market News
Why the Anatara (ASX:ANR) share price is rocketing 19% today
⏸️ Investing
5 multi-million dollar takeover targets
⏸️ Investing
Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited
⏸️ Investing
10 stocks up by more than 50% in the past month
ANR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.
ANR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Oct 2024 | $0.05 | $0.00 | 0.00% | 1,521 | $0.05 | $0.05 | $0.05 |
| 14 Oct 2024 | $0.05 | $0.00 | 0.00% | 18,792 | $0.05 | $0.05 | $0.05 |
| 11 Oct 2024 | $0.05 | $0.00 | 0.00% | 30,703 | $0.05 | $0.05 | $0.05 |
| 10 Oct 2024 | $0.05 | $0.00 | 0.00% | 115,202 | $0.05 | $0.05 | $0.05 |
| 09 Oct 2024 | $0.05 | $-0.01 | -18.52% | 272,235 | $0.05 | $0.05 | $0.05 |
| 08 Oct 2024 | $0.05 | $0.00 | 0.00% | 50,000 | $0.05 | $0.05 | $0.05 |
| 07 Oct 2024 | $0.05 | $-0.01 | -17.86% | 332,647 | $0.06 | $0.06 | $0.05 |
| 04 Oct 2024 | $0.06 | $-0.01 | -14.93% | 103,242 | $0.06 | $0.06 | $0.06 |
| 03 Oct 2024 | $0.07 | $0.00 | 0.00% | 278,952 | $0.07 | $0.07 | $0.06 |
| 01 Oct 2024 | $0.07 | $0.00 | 0.00% | 214,428 | $0.07 | $0.07 | $0.06 |
| 30 Sep 2024 | $0.07 | $0.00 | 0.00% | 83,519 | $0.07 | $0.07 | $0.07 |
| 27 Sep 2024 | $0.07 | $0.00 | 0.00% | 261,889 | $0.07 | $0.07 | $0.07 |
| 26 Sep 2024 | $0.07 | $0.00 | 0.00% | 231,087 | $0.07 | $0.07 | $0.07 |
| 25 Sep 2024 | $0.07 | $0.00 | 0.00% | 1,298,536 | $0.07 | $0.07 | $0.07 |
| 24 Sep 2024 | $0.07 | $0.01 | 17.86% | 1,009,692 | $0.06 | $0.07 | $0.06 |
| 23 Sep 2024 | $0.06 | $0.01 | 20.83% | 336,501 | $0.05 | $0.06 | $0.05 |
| 20 Sep 2024 | $0.05 | $0.00 | 0.00% | 155,424 | $0.05 | $0.05 | $0.05 |
| 19 Sep 2024 | $0.05 | $0.00 | 0.00% | 63,115 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 09 Jul 2024 | David Brookes | Issued | 1,500,000 | $60,000 |
Placement.
|
| 09 Jul 2024 | David Brookes | Issued | 2,500,000 | $100,000 |
Issue of options. As per announcement on 12-07-2024
|
| 09 Jul 2024 | John Michailidis | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 09 Jul 2024 | John Michailidis | Issued | 250,000 | $10,000 |
Placement.
|
| 09 Jul 2024 | Nicholas Haslam | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 11 Dec 2023 | David Brookes | Issued | 750,000 | $16,500 |
Rights issue.
|
| 11 Dec 2023 | David Brookes | Issued | 750,000 | $16,500 |
Rights issue.
|
| 11 Dec 2023 | John Michailidis | Issued | 250,000 | $5,500 |
Rights issue.
|
| 08 Dec 2023 | David Brookes | Issued | 140,000 | $3,080 |
Rights issue.
|
| 08 Dec 2023 | David Brookes | Issued | 725,716 | $15,965 |
Rights issue.
|
| 08 Dec 2023 | John Michailidis | Issued | 200,000 | $4,400 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Lionel Brookes | Executive ChairmanExecutive Director | Jun 2022 |
Dr. Brookes has extensive experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Dr. Brookes has since held Board positions in a number of ASX listed biotechnology companies. Dr. Brookes maintains roles as a clinician and as a biotechnology industry consultant. He is a Member of the audit and risk management committee Member of the remuneration and nominations committee.
|
| Mr John Michailidis | Chief Operating OfficerExecutive Director | Oct 2023 |
Mr Michailidis has more than 30 years of pharmaceutical experience. John is currently the Chief Operating Officer of Anatara and the Managing Director of JEM Pharmaceuticals Pty Ltd. He has gained experience in several senior and executive positions throughout his career, including as Non-Executive Director of Factor Therapeutics Pty Ltd and Australian Diabetes Educators Association, the Chair of Access Community Health, Managing Director of Teva Pharma Australia Pty Ltd and Business Director and Global Head of the Nephrology/Oncology Franchise for F. Hoffman La Roche. John also has CEO experience with growth-stage pharmaceutical companies including Orphan Australia Pty Ltd, Avipep Pty Ltd and Roche Korea Ltd.
|
| Mr Nicholas William Haslam | Non-Executive Director | Dec 2022 |
Mr Haslam is a member of audit and risk management committee Member of the remuneration and nominations committee.
|
| Mr Stephen (Steve) Denaro | Company Secretary |
-
|
|
| Mr Steven Lydeamore | Chief Executive Officer | Dec 2018 |
-
|
| Simon Erskine | Chief Development Officer |
-
|
|
| Steven Lydeamore | Chief Executive Officer |
-
|
|
| John Michailidis | Chief Operating Officer |
-
|
|
| Stephen (Steve) Denaro | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Rtl Group Investments Pty Ltd <The Rtl Investment A/C> | 12,542,857 | 10.46% |
| Ubs Nominees Pty Ltd | 8,494,808 | 7.08% |
| Scintilla Strategic Investments Limited | 6,357,142 | 5.30% |
| Parma Corporation Pty Ltd | 4,667,681 | 3.89% |
| Myeng Pty Ltd | 3,580,211 | 2.99% |
| Mr Bertrand Lalanne | 3,300,000 | 2.75% |
| Himstedt & Co Pty Ltd <The Himstedt Family A/C> | 3,142,857 | 2.62% |
| Calama Holdings Pty Ltd <Mambat Super Fund A/C> | 2,663,987 | 2.22% |
| Mr Michael Andrew Whiting + Mrs Tracey Anne Whiting <Whiting Family S/F A/C> | 2,500,000 | 2.08% |
| Symington Pty Ltd | 2,100,000 | 1.75% |
| Mr Samuel Francis Hunter | 2,080,729 | 1.74% |
| Octifil Pty Ltd | 2,000,000 | 1.67% |
| Mr Brendan Phyland | 1,894,042 | 1.58% |
| Candour Asset Management Pty Ltd | 1,548,056 | 1.29% |
| Gp Securities Pty Ltd | 1,500,000 | 1.25% |
| Slade Technologies Pty Ltd <Embrey Family Superfund A/C> | 1,500,000 | 1.25% |
| Longridge Partners Pty Ltd | 1,400,000 | 1.17% |
| Toucan Trading Pty Ltd | 1,371,429 | 1.14% |
| Dr David Lionel Brookes + Mrs Elisabeth Brookes <Dr Dl Brookes Persnl S/F A/C> | 1,242,858 | 1.04% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 1,096,345 | 0.91% |
